Should 3 years of adjuvant osimertinib be the standard of care for resected Stage IB-IIIA EGFR+ NSCLC?  

Given data presented at ASCO 2020? https://meetinglibrary.asco.org/record/191929/abstract



Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Academic Institution